SHPK and ataxia telangiectasia: PM-specific non-permeable toxin Kv1.3 inhibitors, such as ShK, were shown to strongly decrease the clinical score in EAE-AT models (Beeton et al, 2001a; Yuan et al, 2018) and this effect was ascribed to their action on TEMs.